<DOC>
	<DOC>NCT02732327</DOC>
	<brief_summary>This study will evaluate the effect, safety, and tolerability of ceftazidime-avibactam (CAZ-AVI) plus vancomycin or linezolid compared to standard of care plus vancomycin or linezolid as empiric therapy in febrile neutropenic adults with cancer.</brief_summary>
	<brief_title>Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<criteria>Patients with neutropenic fever who have existing malignancy or have undergone hematopoietic stem cell transplantation Requires hospitalization for intravenous (IV) empiric antibiotic therapy Fungal or viral infection requiring additional therapy Known acute viral hepatitis Known to be human immunodeficiency virus (HIV) positive Expected requirement for hemodialysis while on study therapy Received &gt;24 hours of systemic antibacterial therapy within 72 hours of initiation of inpatient IV study drug Past or current history of epilepsy or seizure disorder Evidence of immediately lifethreatening disease, progressively fatal disease, or life expectancy of 3 months or less.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>